KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple Turns 50: From Garage Startup to AI Crossroads 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
NEW YORK, Jan. 04, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- J.P. Morgan 2017 Healthcare Conference on January 11, 2017 at 5:00 p.m. Pacific Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
